Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients.
Hematology Institute, Soroka University Medical Center, Beer-Sheva, Israel.
Anat
A
Rabinovich
Dana
D
Weiss
Maya
M
Weissman
Victor
V
Novack
Itai
I
Levi
D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D054715:Cardiotoxins / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D011929:Razoxane / Q000008:administration & dosage*; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
D018943:Anthracyclines; D000970:Antineoplastic Agents; D054715:Cardiotoxins; D011929:Razoxane